Skip to content
Abierto

Solicitation

ARPA-H RESILIENT EXTENDED AUTOMATIC CELL THERAPIES (REACT)

ARPA-H-MAI-24-01-02

National Institutes of Health, Advanced Research Projects Agency for Health (Arpa-H). Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).

Response deadline

January 26, 2024 at 2:00 PM EST

Closed 965 days ago. Posted January 17, 2024, first published January 10, 2024. Scheduled to archive February 10, 2024.

Description

As published on SAM.gov.

January 17, 2024 - Amendment 02: This amendment revises the Basis of Estimate and and Tech & Management templates. An updated FAQ document is also posted. January 10, 2024 - Updated FAQs posted.

December 27, 2023 - Amendment 01: This amendment updates the eligiility for Federally Funded Research and Development Centers (FFRDCs) and Government entities. This amendment also adds additional instructions for the Basis of Estimate (BOE). Volume 1 proposals remain due on January 26, 2024. The Advanced Research Projects Agency for-Health (ARPA-H) is soliciting proposals for the Resilient Extended Automatic Cell Therapies (REACT) program using the Master Announcement Instruction (MAI) solicitation strategy.

For more information, please refer to the attached ARPA-H-MAI-24-01, which aims to provide proposers with the ability to scale the level of effort that they spend developing proposal materials with the magnitude of the effort they plan to propose. The MAI introduces a tiered approach to proposal submission for small scale (BIT / BYTE), mid-scale (KILO/MEGA), and large scale (GIG/TERA) efforts. The REACT solicitation described below is soliciting a Module Announcement at the large-scale GIG Module category level.

All awards will be made in the form of an Other Transaction (OT). Specifically, ARPA-H is soliciting innovative proposals for research and development (R&D) in therapeutic development and affordability and improving the way patients manage their own health. Currently many therapeutics are ineffective, not because they are medically unsound, but because of the barriers faced by patients who need them. Limited access and high costs block many patients from benefiting from the newest treatment regimes.

Moreover, many acute and lifelong diseases significantly burden patients with continuous management of their health through pills, injections, blood draws, or even invasive surgery. This burden often leads to low treatment fidelity and poor health outcomes for the patient. Improving health and wellness requires simultaneous resolution of limitations in access and affordability.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. January 10, 2024

    Solicitation

    Due January 26, 2024 at 2:00 PM EST. SAM.gov, notice 4714832a60c24582a420c2a0ce3b6957

  2. January 17, 2024

    Solicitation

    Due January 26, 2024 at 2:00 PM EST. SAM.gov, notice ac0008be64dd4fdbad8c4e8197730907

Points of contact